GlassScriptPhysician profile
Andrew Hirsch
NPI 1275588972
$22,718.68
in general payments reported to CMS, 2019-2025
44 companies · $6,467 in 2025
The $6,467 reported for 2025 was more than what 85% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,812 · 2020: $1,032 · 2021: $1,576 · 2022: $1,856 · 2023: $1,643 · 2024: $2,333 · 2025: $6,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,169 · Consulting Fee: $3,500 · Travel and Lodging: $774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,169.26 |
| Consulting Fee | $3,500.00 |
| Travel and Lodging | $773.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $8,805.62 | 2019-2025 | Xolair |
| Optinose US, INC. | $3,595.43 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,146.36 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,464.03 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $647.50 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $621.74 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $541.24 | 2019-2025 | Dupixent |
| Alk-Abello, INC | $458.27 | 2019-2025 | Grastek, Odactra, Ragwitek |
| Teva Pharmaceuticals USA, INC. | $359.64 | 2020-2023 | Airduo Digihaler |
| Pfizer INC. | $356.56 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $294.57 | 2020-2025 | Eohilia, Cuvitru, Hyqvia |
| Kaleo, INC. | $282.67 | 2019-2025 | Auvi-Q |
| Amneal Pharmaceuticals LLC | $240.00 | 2024 | |
| Amgen INC. | $207.71 | 2021-2025 | Tezspire |
| Covis Pharma Gmbh | $167.52 | 2019-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Hirsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.